Prescribers, patients and specialty care centers no longer will be required to enroll in safety monitoring programs for two drugs used to treat low platelet counts, following changes to their risk evaluation and mitigation strategies.
The list of participating companies in the 13th Annual Drug Store News Group Industry Issues conference — which will be held Tuesday, Nov. 29, at the highly prestigious New York Athletic Club — reads like a “who’s who” of pharmacy retailing.
Biotechnology company Signum Biosciences has entered a collaborative agreement with GlaxoSmithKline whereby GSK will receive the exclusive right to Signum's proprietary phosphatase screening technology.
Sales in the digestives aisle going forward look positive, especially as an aging population begins paying closer attention to healthy diets, including the right amount of dietary fiber to keep things “regular” and supplementation with probiotics for overall digestive health.
As the clock winds down on the patent exclusivity of the industry’s biggest blockbuster drug in November, speculation continues to grow that Pfizer will look to flip the switch on an OTC version of Lipitor (atorvastatin) before generic competition whittles away at the $7 billion behemoth.